ACV meeting #30, 14 January 2022

The meeting of the Advisory Committee on Vaccines (ACV).

The committee provided advice on two applications:

• major variation (change to dose regimen) for a vaccine with provisional registration for active immunisation to prevent COVID-19 (product name Comirnaty; active ingredient Tozinameran; sponsor Pfizer Australia Pty Ltd) that had been under evaluation from October 2021
• major variation (change to dose regimen) for a vaccine with provisional registration for active immunisation to prevent COVID-19 (product name Vaxzevria; active ingredient ChAdOx-1-S; sponsor AstraZeneca Pty Ltd) that had been under evaluation from November 2021.

Members

Membership comprises professionals with expertise in specific scientific, medical or clinical fields, or consumer health issues.